Evidence map›Paper›PMID 39993239›Full record

ArticleBlood advances2025

Post transplant maintenance therapy with newly FDA-approved revumenib for high-risk KMT2Ar acute leukemia.

Olayinka Okeleji, David McCall, Amber Gibson, Miriam B Garcia, Cesar Nunez, Michael Roth, Jeremy Connors, Demetrios Petropoulos, Priti Tewari, Branko Cuglievan and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Olayinka OkelejiDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0009-0005-3770-1139
David McCallLeukemia Section, Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0003-2297-9670
Amber GibsonLeukemia Section, Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-9146-4702
Miriam B GarciaLeukemia Section, Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-2978-2267
Cesar NunezLeukemia Section, Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Michael RothLeukemia Section, Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-6411-8353
Jeremy ConnorsStem Cell Transplantation and Cellular Therapy Section, Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0003-2817-8890
Demetrios PetropoulosStem Cell Transplantation and Cellular Therapy Section, Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Priti TewariStem Cell Transplantation and Cellular Therapy Section, Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0003-4819-5276
Branko CuglievanLeukemia Section, Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-6917-2244
Irtiza N SheikhStem Cell Transplantation and Cellular Therapy Section, Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0003-4869-8818

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39993239
PMCPMC12034065

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.